CASBF
Price
Loading...
Change
-$0.00 (-0.00%)
Updated
Loading...
Capitalization
1.96B
Intraday BUY SELL Signals
CRLBF
Price
$1.07
Change
-$0.09 (-7.76%)
Updated
Nov 13 closing price
Capitalization
382.65M
124 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CASBF vs CRLBF

Header iconCASBF vs CRLBF Comparison
Open Charts CASBF vs CRLBFBanner chart's image
CANSINO BIOLOGICS
PriceLoading...
Change-$0.00 (-0.00%)
Volume$151
Capitalization1.96B
Cresco Labs
Price$1.07
Change-$0.09 (-7.76%)
Volume$446.47K
Capitalization382.65M
CASBF vs CRLBF Comparison Chart in %
CASBF
Daily Signal:
Gain/Loss:
CRLBF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CASBF vs. CRLBF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CASBF is a Hold and CRLBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CASBF: $5.60 vs. CRLBF: $1.07)
Brand notoriety: CASBF and CRLBF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CASBF: 87% vs. CRLBF: 56%
Market capitalization -- CASBF: $1.96B vs. CRLBF: $382.65M
CASBF [@Pharmaceuticals: Generic] is valued at $1.96B. CRLBF’s [@Pharmaceuticals: Generic] market capitalization is $382.65M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CASBF’s FA Score shows that 1 FA rating(s) are green whileCRLBF’s FA Score has 0 green FA rating(s).

  • CASBF’s FA Score: 1 green, 4 red.
  • CRLBF’s FA Score: 0 green, 5 red.
According to our system of comparison, CASBF is a better buy in the long-term than CRLBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CASBF’s TA Score shows that 5 TA indicator(s) are bullish while CRLBF’s TA Score has 2 bullish TA indicator(s).

  • CASBF’s TA Score: 5 bullish, 3 bearish.
  • CRLBF’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CASBF is a better buy in the short-term than CRLBF.

Price Growth

CASBF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while CRLBF (@Pharmaceuticals: Generic) price change was +7.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.58%. For the same industry, the average monthly price growth was -3.79%, and the average quarterly price growth was +30.64%.

Reported Earning Dates

CRLBF is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CASBF($1.96B) has a higher market cap than CRLBF($383M). CASBF YTD gains are higher at: 39.965 vs. CRLBF (26.952). CRLBF has higher annual earnings (EBITDA): 136M vs. CASBF (-1.88B). CASBF has more cash in the bank: 4.02B vs. CRLBF (147M). CRLBF has less debt than CASBF: CRLBF (631M) vs CASBF (2.12B). CRLBF has higher revenues than CASBF: CRLBF (685M) vs CASBF (359M).
CASBFCRLBFCASBF / CRLBF
Capitalization1.96B383M511%
EBITDA-1.88B136M-1,385%
Gain YTD39.96526.952148%
P/E RatioN/AN/A-
Revenue359M685M52%
Total Cash4.02B147M2,731%
Total Debt2.12B631M336%
FUNDAMENTALS RATINGS
CASBF vs CRLBF: Fundamental Ratings
CASBF
CRLBF
OUTLOOK RATING
1..100
3267
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
4444
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASBF's Valuation (11) in the null industry is significantly better than the same rating for CRLBF (81). This means that CASBF’s stock grew significantly faster than CRLBF’s over the last 12 months.

CASBF's Profit vs Risk Rating (100) in the null industry is in the same range as CRLBF (100). This means that CASBF’s stock grew similarly to CRLBF’s over the last 12 months.

CRLBF's SMR Rating (93) in the null industry is in the same range as CASBF (96). This means that CRLBF’s stock grew similarly to CASBF’s over the last 12 months.

CRLBF's Price Growth Rating (44) in the null industry is in the same range as CASBF (44). This means that CRLBF’s stock grew similarly to CASBF’s over the last 12 months.

CASBF's P/E Growth Rating (81) in the null industry is in the same range as CRLBF (100). This means that CASBF’s stock grew similarly to CRLBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CASBFCRLBF
RSI
ODDS (%)
Bullish Trend 3 days ago
45%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
47%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
42%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend about 1 month ago
80%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
56%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CASBF
Daily Signal:
Gain/Loss:
CRLBF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGRTX86.170.27
+0.31%
JPMorgan US Value R2
DGOCX28.290.05
+0.18%
Davis Opportunity C
EMQAX10.03N/A
N/A
Ashmore Emerging Markets Active Eq A
DWOAX21.84-0.02
-0.09%
BNY Mellon Research Growth A
MPSSX22.07-0.03
-0.14%
BNY Mellon Small Cap Multi-Strategy M

CASBF and

Correlation & Price change

A.I.dvisor tells us that CASBF and CRLBF have been poorly correlated (+3% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASBF and CRLBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASBF
1D Price
Change %
CASBF100%
N/A
CRLBF - CASBF
3%
Poorly correlated
-4.13%
CNTMF - CASBF
2%
Poorly correlated
-7.47%
BUDZ - CASBF
2%
Poorly correlated
-9.62%
CBWTF - CASBF
1%
Poorly correlated
+1.75%
CPHRF - CASBF
0%
Poorly correlated
-0.18%
More

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TSNDF. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
-4.13%
TSNDF - CRLBF
76%
Closely correlated
-8.59%
CURLF - CRLBF
76%
Closely correlated
-1.42%
TCNNF - CRLBF
75%
Closely correlated
-0.86%
JUSHF - CRLBF
74%
Closely correlated
-10.77%
GTBIF - CRLBF
72%
Closely correlated
-3.45%
More